



## ASX& MEDIA RELEASE

### Peplin to present at the 2008 Thomas Weisel Partners Healthcare Conference

**EMERYVILLE, California and BRISBANE, Australia, 28 August 2008: Peplin, Inc.** (ASX:PLI) announced today that Chief Commercial Officer George Mahaffey will present at the Thomas Weisel Partners Annual Healthcare Conference at the Four Seasons Hotel in Boston, MA on Thursday, September 4 at 11.30am US Eastern Standard Time (1.30 am on Friday, September 5 AEST). A live webcast of the presentation will be available at <http://www.veracast.com/webcasts/twp/healthcare08/98115341.cfm> or via Peplin's website at [www.peplin.com](http://www.peplin.com).

An archive of the webcast will be available on our website [www.peplin.com](http://www.peplin.com) for replay for thirty days following the live presentation.

#### Further information:

Tom Wiggans  
Chief Executive Officer  
Tel: +1-510-653 9700  
[tom.wiggans@peplin.com](mailto:tom.wiggans@peplin.com)

#### Media:

Andrew Collett  
Hill & Knowlton  
Tel: 02-9286 1224  
[acollett@hillandknowlton.com.au](mailto:acollett@hillandknowlton.com.au)

#### ABOUT PEPLIN

Peplin is a development stage specialty pharmaceutical company focused on advancing and commercializing innovative medical dermatology products. Peplin is currently developing PEP005 (ingenol mebutate), which is the first in a new class of compounds and which is derived from the sap of *Euphorbia peplus*, or *E. peplus*, a rapidly growing, readily available plant commonly referred to as petty spurge or radium weed. *E. peplus* has a long history of traditional use for a variety of conditions, including the topical self-treatment of various skin disorders, including skin cancer and pre-cancerous skin lesions. Peplin's lead product candidate is a patient-applied topical gel containing ingenol mebutate, a compound the use of which Peplin has patented for the treatment of actinic keratosis, or AK. This product candidate is currently in Phase II clinical trials and is referred to as PEP005 (ingenol mebutate) Gel.

#### FORWARD LOOKING STATEMENTS

This press release contains "forward-looking statements" as defined under U.S. federal securities laws, including, but not limited to, Peplin's clinical development plan referred to herein. These forward-looking statements can be identified through the use of words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "may," "will," and variations of these words or similar expressions.

#### PEPLIN, INC.

6475 Christie Avenue, Emeryville, CA 94608, USA  
Tel: +1-510-653 9700 Fax: +1-510-653 9704

Level 2, Brisbane Portal, 1 Breakfast Creek Road, Newstead, QLD, 4006, Australia  
Tel: +61-7-3250 1200 Fax: +61-7-3250 1299

Forward looking statements are based on management's current, preliminary expectations and actual results could differ materially as a result of various risks and uncertainties, including, but not limited to, delays in the completion of clinical trials resulting from, among other things, ambiguous or negative interim results, failure to close the acquisition of Neosil, Inc., unforeseen safety issues, failure to conduct the clinical trials in accordance with regulatory requirements or clinical protocols, suspension or termination of a clinical trial by the FDA or other regulatory authorities, failure to obtain the stockholder approval necessary to approve the pending private placement, lack of adequate funding to continue a clinical trial and other important factors disclosed from time to time in Peplin's disclosures to the ASX. Forward-looking statements speak only as of the date they were made. No undue reliance should be placed on any forward-looking statements. Such information is subject to change, and we undertake no obligation to update such statements.